Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11248-021-00268-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preface to genomics of rheumatic disease.
Best Pract Res Clin Rheumatol
December 2024
Discipline of Medicine, Division of Rheumatology, Memorial University, St. John's, NL, Canada; Rheumatology, Newfoundland and Labrador Health Services, St. John's, NL, Canada. Electronic address:
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
Eur J Cancer
September 2024
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
Background: The monarchE and NATALEE trials demonstrated the benefit of CDK4/6 inhibitor (CDK4/6i) therapy in adjuvant breast cancer (BC) treatment. Patient selection, based on clinical characteristics, delineated those at high (monarchE) and high/intermediate recurrence risk (NATALEE). This study employed a historical patient cohort to describe the proportion and prognosis of patients eligible for adjuvant CDK4/6i trials.
View Article and Find Full Text PDFCorrection: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
February 2024
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Article Synopsis
- The text discusses a necessary correction to a previously published article identified by the DOI 10.1055/a-2238-3153.
- It highlights the importance of accuracy in scientific publications and the impact of corrections on the integrity of research.
- This rectification ensures that readers and researchers rely on correct information when referencing the work.
Preface 25 Years of Current Genomics.
Curr Genomics
February 2024
Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
February 2024
Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Introduction: Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!